

Literaturverzeichnis zum Titelthema: Neu in der Nierentransplantation

von Professor Dr. Daniel Zecher und Professor Dr. Bernhard Banas, MBA

Bayerisches Ärzteblatt 12/2024, Seite 560 ff.

1. Jahresbericht der Deutschen Stiftung Organtransplantation, online verfügbar unter: <https://dso.de/SiteCollectionDocuments/DSO-Jahresbericht%202023.pdf>
2. Hariharan S, Israni AK, Danovitch G. Long-Term Survival after Kidney Transplantation. *N Engl J Med* 2021; 385(8):729-743.
3. Hauptenthal F, Rahn J, Maggi F, et al.; TTVguideTX consortium partners: A multicentre, patient- and assessor-blinded, non-inferiority, randomised and controlled phase II trial to compare standard and torque teno virus-guided immunosuppression in kidney transplant recipients in the first year after transplantation: TTVguideIT. *Trials* 2023; 24(1):213.
4. Sellares J, de Freitas DG, Mengel M, et al.: Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. *Am J Transplant* 2012; 12: 388-99.
5. Schinstock CA, Mannon RB, Budde K, et al.: Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantation Society Working Group. *Transplantation* 2020; 104: 911-22.
6. Doberer K, Duerr M, Halloran PF, et al.: A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection. *J Am Soc Nephrol* 2021; 32: 708-22.
7. Kulkarni S, Kirkiles-Smith NC, Deng YH, et al.: Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial. *Am J Transplant* 2017; 17: 682-91.
8. Eskandary F, Regele H, Baumann L, et al.: A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection. *J Am Soc Nephrol* 2018; 29: 591-605.
9. Lemal R, Blandin L, Uro-Coste C, et al.: Daratumumab treatment in six highly sensitised solid organ transplant recipients: A case series and literature review. *HLA* 2024; 103: e15458.
10. de Nattes T, Kaveri R, Farce F, et al.: Daratumumab for antibody-mediated rejection: Is it time to target the real culprit? *Am J Transplant* 2023; 23: 1990-4.
11. Zhu L, Guo Z, Zhao D, et al.: Case report: Daratumumab for treatment of refractory late or chronic active antibody-mediated rejection in renal allograft recipients with high levels of de novo donor-specific antibodies. *Front Immunol* 2022; 13: 1087597.

12. Mayer KA, Schrezenmeier E, Diebold M, et al.: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection. N Engl J Med 2024.
13. Meier-Kriesche HU, Kaplan B: Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis. Transplantation 2002; 74: 1377-81.
14. Böhmig G, Müller-Sacherer T, Viklicky O. Kidney Paired Donation-European Transnational Experience in Adults and Opportunities for Pediatric Kidney Transplantation. Pediatr Transplant 2024 (6):e14840.
15. Entwurf eines Dritten Gesetzes zur Änderung des Transplantationsgesetzes – Novellierung der Regelungen zur Lebendorganspende und weitere Änderungen, online verfügbar unter: https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/3_Downloads/Gesetze_und_Verordnungen/GuV/O/GE_Novellierung_der_Regelungen_zur_Lebendorganspende_Kabinett.pdf